SYNAPS Dx Announces DISCERN, Minimally Invasive Test for Accurate Diagnosis of Alzheimer’s Disease, Receives First-in-Category PLA Codes
ROCKVILLE, Md.--(BUSINESS WIRE)--#AlzheimersDisease--SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of diagnostics for neurodegenerative disorders and conditions, including Alzheimer’s Disease (AD), announces that DISCERN™, ...
